Fluconazol: Vergleich von Pharmakokinetik, Therapie und Empfindlichkeit der Sproßpilze in vitro
- 1 October 1996
- Vol. 39, 51-57
- https://doi.org/10.1111/j.1439-0507.1996.tb00529.x
Abstract
Fluconazole penetrates well into the tissues and body fluids which were examined and achieves rapid equilibration between the different compartments. The pharmacokinetics of fluconazole are independent of the dose after oral or intravenous administration. This finding, together with the drug's slow elimination (t1/2 30 h) facilitate the estimation of the therapeutically effective dosage. The concentrations of fluconazole measured in blood can be extrapolated to the concentrations in tissue (lung, brain, gynecological tissues), body fluids (sputum, saliva, vaginal secretions) and exudates. The concentration of fluconazole in cerebrospinal fluid and in the vitreous humour of the eye is ca. 80% of that in blood. Fluconazole is predominantly excreted in the urine in the unchanged form, which explains the 10 to 20 fold higher concentration of the drug in urine relative to blood. Although this pharmacokinetic profile favours the use of fluconazole in mycotic infections of the urinary tract it also means that the dose of the drug may have to be adapted to lower regimens in the systemic treatment of patients with restricted kidney function. The in vitro and in vivo susceptibility of the yeasts correlates with the concentrations of fluconazole measured in the different compartments of the body.Keywords
This publication has 26 references indexed in Scilit:
- High-Dose Fluconazole Therapy for Cryptococcal Meningitis in Patients with AIDSClinical Infectious Diseases, 1996
- Fluconazole penetration in cerebral parenchyma in humans at steady stateAntimicrobial Agents and Chemotherapy, 1995
- High-Dose Fluconazole for Treatment of Cryptococcal Disease in Patients with Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 1994
- A Controlled Trial of Fluconazole or Amphotericin B to Prevent Relapse of Cryptococcal Meningitis in Patients with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1992
- Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasisAntimicrobial Agents and Chemotherapy, 1990
- Pharmacokinetics and Tissue Penetration of Fluconazole in HumansClinical Infectious Diseases, 1990
- Sputum levels of fluconazole in humansAntimicrobial Agents and Chemotherapy, 1989
- COMPARISON OF FLUCONAZOLE AND KETOCONAZOLE FOR OROPHARYNGEAL CANDIDIASIS IN AIDSThe Lancet, 1989
- Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitisAntimicrobial Agents and Chemotherapy, 1988
- Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humansAntimicrobial Agents and Chemotherapy, 1985